CRISPR-Based COVID-19 Testing: Toward Next-Generation Point-of-Care Diagnostics

As the COVID-19 pandemic continues, people are becoming infected at an alarming rate, individuals are unknowingly spreading disease, and more lives are lost every day. There is an immediate need for a simple, rapid, early and sensitive point-of-care testing for COVID-19 disease. However, current testing approaches do not meet such need. Recently, clustered regularly interspaced short palindromic repeats (CRISPR)-based detection methods have received substantial attention for nucleic acid-based molecular testing due to their simplicity, high sensitivity and specificity. This review explores the various CRISPR-based COVID-19 detection methods and related diagnostic devices. As with any emerging technology, CRISPR/Cas-based nucleic acid testing methods have several challenges that must be overcome for practical applications in clinics and hospitals. More importantly, these detection methods are not limited to COVID-19 but can be applied to detect any type of pathogen, virus, and fungi that may threaten humans, agriculture, and food industries in resource-limited settings. CRISPR/Cas-based detection methods have the potential to become simpler, more reliable, more affordable, and faster in the near future, which is highly important for achieving point-of-care diagnostics.

Automated summary

As the COVID-19 pandemic continues, there is a need for a simple, rapid, early and sensitive point-of-care testing for the disease. CRISPR-based detection methods have gained attention for their simplicity, high sensitivity, and specificity, but face challenges for practical applications. These methods have the potential to become simpler, more reliable, more affordable, and faster, which is crucial for achieving point-of-care diagnostics.